name: Calcified body and greater cornua of hyoid


name: Epiphyseal stippling (hips, distal and proximal humeri, proximal and distal femora, distal fibulae, proximal and distal tibiae, distal radii and ulnae)


name: Metaphyseal flaring (distal femora, proximal tibiae)


name: Transmural granulomatous inflammation with 'skip lesions'


name: Aphthous ulcers (lips, gingiva, buccal mucosa)


name: Hyposthenuria (inability to concentrate urine normally)


name: Valvular heart disease Aortic valve stenosis


name: Fetid breath due to increased dimethylsulfide


name: 'Globoid multinucleated cells' in brain tissue


name: Lateral curving of inferior scapular angle


name: Joint stiffness (neck, shoulder, elbow, hips)


name: MRI shows decreased signal intensities in the basal ganglia


name: Testicular biopsy shows hypospermatogenesis


name: Increased thyroid-stimulating hormone (TSH)


name: Alopecia, partial, primarily involving scalp and eyebrows


name: Increased hepatic parenchymal cell stainable iron


name: Muscle fibers may contain abnormal polysaccharide


name: Decreased erythrocyte 2,3-diphosphoglycerate (2,3-DPG)


name: No increase of muscle lactate with ischemic exercise testing


name: Muscle pain and cramps following exercise


name: Diaphragmatic defect, often unilateral and left-sided


name: Urinary excretion of retinol-binding proteins (RBP) and vitamin D-binding proteins (DBP)


name: Pulmonary hypoplasia secondary to diaphragmatic hernia


name: Cortisol does not decrease on dexamethasone suppression test


name: Individuals can stand or walk with support by 4 to 6 years of age


name: Axonal swelling of spinal nerve roots and cranial nerves


name: Sural nerve biopsy shows absence of large myelinated fibers


name: Decreased motor and sensory nerve conduction velocities


name: Hallucinatory psychosis develops during adolescence


name: Progressive distal and proximal symmetric limb weakness


name: Adrenal glands may be normal, atrophic, or slightly enlarged


name: Decreased activity of thiopurine S-methyltransferase


name: Decreased metabolism of thiopurine drugs


name: Increased toxic thioguanine nucleotides (TGNs) on standard doses of thiopurine drugs


name: Myelosuppression develops on standard doses of thiopurine drugs


name: Hematopoietic toxicity develops on standard doses of thiopurine drugs


name: Erythematous papular skin eruption (infancy)


name: Massive calcium deposition in mid- and lower dermis


name: Painful bluish-red papules or nodules (fingers, toes, nose, cheek, ears)


name: Healed areas are atrophic and hypopigmented


name: Deep inflammatory perivascular infiltrate with granular deposits of immunoglobulins and complement along basement membrane


name: Preauricular tag, isolated (skin covered and composed of elastic cartilage usually located anterior to the tragus or ascending crus of the helix but can be elsewhere on the ear or face)


name: Ectopic periarticular calcified masses, painful (hip, elbow, shoulder)


name: Progressive deposition of basic calcium phosphate crystals


name: Normal to elevated serum 1,25-dihydroxycholecalciferol (calcitriol)


name: Deposition of calcium phosphate crystals in skin and subcutaneous tissues


name: V-shaped flaring of distal femoral metaphyses


name: Granular osmiophilic deposits (GROD) in cells resulting in 'fingerprint' profiles ultrastructurally


name: Granular osmiophilic deposits (GROD) in cells resulting in 'curvilinear' profiles ultrastructurally


name: Mucosal and submucosal inflammation limited to colon, always involving rectum


name: Benign tumors of the eye, heart, and lungs


name: BREAST CANCER, INVASIVE, SUSCEPTIBILITY TO


name: Congenital, upward displacement of the scapula (Sprengel deformity)


name: Cervical segmentation defects (Klippel-Feil sequence)


name: Cataract, congenital (nuclear, sutural, or stellate cortical)


name: Cataract, progressive, juvenile-onset (lamellar, cortical, nuclear embryonic, or Y-sutural)


name: Cataract, adult-onset (punctate cortical)


name: Hearing loss, unilateral or bilateral, conductive or mixed conductive/sensorineural


name: Right pulmonary artery, anomalous origin of


name: INTRAOCULAR PRESSURE QUANTITATIVE TRAIT LOCUS


name: Thick, maloriented superior cerebellar peduncles


name: Decreased CSF pyridoxal 5-prime-phosphate (PLP)


name: Aberrant skin dimples (elbows and knees)


name: Balanced translocation carrier 46,XY,+(11:18)(p13:q21)mat


name: Hearing loss, sensorineural, severe to profound


name: Thickening of the glomerular basement membrane on renal biopsy


name: Deposition of complement component C3 in glomerular basement membrane


name: Continuous activation of the alternative complement pathway


name: Increased susceptibility to certain bacterial infections, especially Neisseria meningitidis


name: Normal levels of complement factor H, but impaired function


name: Single, bilateral, symmetric papular/nodular lesion in the midline plantar region of the heel (0.5 - 1 cm diameter)


name: Mature adipose tissue enveloped in collagenous fibrous sheaths


name: Mature adipocytes surrounded by edematous interstitial component


name: HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 11


name: Disconnection of keratin intermediate filaments from desmosomes


name: Subtelomeric deletion of long arm of chromosome 3 (3q29)


name: HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2


name: HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1


name: Retinitis pigmentosa (onset in infancy to early childhood)


name: Grimacing or unusual smile with almost closing of the eyes


name: pseudoexfoliation of lens (physical finding)


name: Chondrocytes showed large lamellar dilatations of rough endoplasmic reticulum on electron microscopy


name: Small head circumference (lower end of normal)


name: PANCREATITIS, CHRONIC, SUSCEPTIBILITY TO


name: Autonomic reflex asystolic syncopal events


name: Rectal pain, episodic, triggered by defecation


name: Mandibular and submandibular pain, episodic, triggered by eating and yawning


name: Reddish discoloration, episodic, associated with pain


name: Skin flushing, episodic, associated with pain


name: MRI shows diffuse white matter hyperintensities on T2-weighted imaging


name: Paralysis and atrophy of distal lower limb muscles over time


name: Myotonia, potassium-sensitive (may be responsive to acetazolamide)


name: EMG in myotonia permanens shows continuous myotonic activity


name: Dental decay due to recurrent bacterial periodontitis


name: Neutrophils show disorganized lysosomal compartments on ultrastructural analysis


name: Decreased numbers of natural killer cells (NK)


name: Pulmonary fibrosis due to recurrent infections


name: Dislocated radial head (anteriorly and laterally)


name: Multiple giant cell granulomas (bones, joints, soft tissues)


name: Pigmented micronodular adrenal dysplasia


name: Testicular Sertoli cell tumor, calcified


name: Increased serum creatine kinase during episodes


name: EMG shows polyphasic continuous motor unit discharges


name: Low-normal platelet count (89-290 x 10(9)/L)


name: Normal platelet aggregation studies with ADP, collagen, and ristocetin


name: Asymptomatic bleeding tendencies (petechiae, epistaxis, mucosal bleeding)


name: Upward tented eyebrows (unilateral or bilateral)


name: PLASMODIUM FALCIPARUM FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1


name: MYCOBACTERIUM TUBERCULOSIS, PROTECTION AGAINST


name: Secondary generalized tonic-clonic seizures may occur


name: Seizures occur in clusters over 1 or several days


name: Seizures often begin focally with head and eye deviation


name: Ictal EEG shows focal onset, often posterior region of brain


name: Increased error rates of memory-guided saccades


name: Recurrent fractures (hypophosphatasia only)


name: Pathologic fractures (hypophosphatasia only)


name: Long bone pseudofractures (hypophosphatasia only)


name: Calcium pyrophosphate arthropathy (hypophosphatasia only)


name: Metatarsal stress fracture (hypophosphatasia only)


name: Hyperpigmented skin patches (face, neck, trunk, limbs, lip, oral mucosa, palms, and soles)


name: Hyperkeratosis with increased melanin in epidermis, especially basal cell layer and tips of rete ridges


name: FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 5


name: Prominent involvement of the quadriceps femoris muscles


name: Prominent involvement of the biceps brachii muscles


name: Neurofibrillary MAPT (tau)-positive tangles


name: LUNG CANCER, PROTECTION AGAINST, IN SMOKERS


name: End stage renal disease (age 6-35 years)


name: Renal tubular cell atrophy with corticomedullary cysts


name: FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 4


name: HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO


name: Unilateral hypoplasia of the depressor anguli oris muscle


name: Unilateral weakness of the depressor anguli oris muscle


name: Amber, translucent coloration (primary teeth)


name: Obliteration of pulp chambers following eruption (primary teeth)


name: Thistle-shaped pulp chambers (secondary teeth)


name: PARKINSON DISEASE 6, LATE-ONSET, SUSCEPTIBILITY TO


name: SLC35A1, 2-BP DEL, 277G AND 281C, AND 147T-C


name: FOXL2, 15-BP DUP, NT684, ALANINE TRACT EXPANSION


name: Decreased height compared to unaffected siblings


name: Osteoarthritis (hips, knees, shoulders, wrists, hands)


name: Type 2 vitreous phenotype (irregularly thickened fiber bundles throughout vitreous cavity)


name: Mildly decreased intelligence has been reported


name: Cores extend along length of muscle fiber


name: Decreased ossification underlying the skin defect


name: Circumscribed transparent membrane on the scalp vertex may be ulcerated


name: Peripheral arthritis (oligoarticular or polyarticular)


name: Terminal transverse defects, asymmetric (minimal to absence of a limb)


name: Dystonia, episodic, primary affects hands and feet


name: Epilepsy, Childhood Absence, Susceptibility To, 4


name: Three concentric rings of hyperautofluorescence - around the fovea, along the vascular arcades, and in the far periphery


name: Absent rod-and cone-mediated responses on ERG (late)


name: Hearing loss, sensorineural (bilateral, prelingual)


name: Distal muscle weakness and atrophy due to motor neuronopathy


name: EMG shows neurogenic changes and denervation


name: Sural nerve biopsy shows normal findings


name: Distal muscle atrophy due to denervation


name: Scapuloperoneal muscular atrophy due to denervation


name: Activation of the alternative complement pathway and depletion of complement components


name: Decreased serum complement factor B (CFB, 138470)


name: Decreased serum complement factor H (CFH, 134370)


name: Increased susceptibility to Streptococcus pneumoniae infections


name: Increased susceptibility to Haemophilus influenzae infections


name: Hypoplasia of the thyroid gland in some patients


name: Serum thyroxine may be decreased or normal


name: Hearing loss begins with loss of high frequencies


name: STAT5B, 1-BP DEL, EXON 13/INTRON 13 JUNCTION


name: 'Compensated hypothyroidism' with increased TSH and normal T4


name: Intracellular accumulation of material resulting in curvilinear profiles on ultrastructural analysis


name: Intracellular accumulation of material resulting in fingerprint profiles on ultrastructural analysis


name: Absent-decreased prolyl 3-hydroxylation at collagen I alpha-1 pro986


name: MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 1


name: Undertubulation (lack of diaphyseal modeling)


name: Ictal EEG shows focal onset in central, parietal, or temporal regions


name: Mildly decreased to low-normal platelet count (80-150 x 10(9)/L)


name: Bleeding time normal to mildly prolonged


name: Reduced platelet aggregation response to adenosine 5'-diphosphate (ADP)


name: Absent platelet aggregation response to epinephrine


name: Normal platelet aggregation response to ristocetin and arachidonic acid (AA)


name: MACULAR DEGENERATION, AGE-RELATED, 2, SUSCEPTIBILITY TO


name: Distal upper limb involvement may occur later


name: Distal sensory impairment of touch, vibration, proprioception


name: Secondary axonal degeneration and regeneration


name: Prolonged brainstem auditory evoked potentials (BAEP)


name: Increased number of skin folds (neck, abdomen, axillae)


name: INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST


name: Small joint laxity (especially hands and elbows)


name: Mild metaphyseal irregularities (upper femurs and distal tibiae)


name: Ulnar deviation of fingers (neonate, resolved by early childhood)


name: Absent carpal ossification center (age 5)


name: Absent metacarpal ossification center (age 5)


name: Abnormal transferrin isoelectric focusing (IEF)


name: Increased disialo- and asialotransferrin


name: Decreased lipid-linked oligosaccharides (LLO)


name: Persistence of corneodesmosomes in stratum corneum


name: CHIT1, GLY354ARG, LEU385LEU, AND 4-BP DEL


name: Arthralgia/arthritis (knee, elbow, shoulder)


name: Arthralgia/arthritis (wrist, interphalangeal joints)


name: Increased alpha/beta globin ratio in reticulocytes


name: Low-normal platelet count in carrier females


name: Intraocular retrolental masses, bilateral ('pseudoglioma')


name: Blindness in infancy or very early childhood


name: Histopathology shows rosettes of immature retinal cells in vascular connective tissue


name: Restricted joint mobility (shoulders, elbows, hips)


name: Calvarial thickening (parietal and occipital area)


name: Marked pneumatization of paranasal sinuses


name: Neurodevelopmental impairment (early-onset form)


name: Sensorineural hearing loss (early-onset form)


name: Increased activity of the PRPP synthetase 1 enzyme


name: Cortical punctate or pulverulent opacities (in carrier females)


name: Posterior subcapsular opacities of the lens (in carrier females)


name: Decreased otoacoustic emission amplitude


name: MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 1


name: Normal to near-normal visual acuity in carrier females (20/30-20/20)


name: Fine lamellar white opacities on slit lamp exam in carrier females


name: Near complete loss of peripheral retinal pigment in males


name: Peppered pigmentary mottling of peripheral retinal pigment in carrier females


name: Myringotomy and insertion of tympanic ventilation tube


name: Esophagus (including hiatus hernia) operations NOS (procedure)


name: Insertion of catheter into urinary bladder


name: Blood ketone test or reagent strip, each


name: Cervical traction device, with inflatable air bladder(s)


name: Manual wheelchair accessory, gear reduction drive wheel, each


name: Manual wheelchair accessory, wheel braking system and lock, complete, each


name: Power wheelchair accessory, hand or chin control interface, mini-proportional remote joystick, proportional, including fixed mounting hardware


name: Power wheelchair accessory, harness for upgrade to expandable controller, including all fasteners, connectors and mounting hardware, each


name: Power wheelchair accessory, lithium-based battery, each


name: Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes


name: Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes


name: Left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function


name: Left ventricular ejection fraction (lvef) not performed or documented


name: Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy


name: Lower extremity neurological exam performed and documented


name: Lower extremity neurological exam not performed


name: Footwear evaluation performed and documented


name: Clinician documented that patient was not an eligible candidate for footwear evaluation measure


name: Bmi is documented above normal parameters and a follow-up plan is documented (G8417)


name: Bmi is documented below normal parameters and a follow-up plan is documented (G8418)


name: Bmi documented outside normal parameters, no follow-up plan documented, no reason given (G8419)


name: Bmi is documented within normal parameters and no follow-up plan is required (G8420)


name: Bmi not documented and no reason is given (G8421)


name: Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an acute health crisis where time is of the essence and delay of treatment would jeopardize the patient's health status)


name: Screening for depression is documented as being positive and a follow-up plan is documented


name: Depression screening not documented, reason not given


name: Screening for depression not completed, documented patient or medical reason


name: Beta-blocker therapy for lvef <=40% not prescribed for reasons documented by the clinician (e.g., low blood pressure, fluid overload, asthma, patients recently treated with an intravenous positive inotropic agent, allergy, intolerance, other medical reasons, patient declined, other patient reasons)


name: Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed


name: Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy not prescribed for reasons documented by the clinician (e.g., allergy, intolerance, pregnancy, renal failure due to ace inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (e.g., patient declined, other patient reasons)


name: Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy not prescribed, reason not given


name: Blood pressure measurement not performed or documented, reason not given


name: Influenza immunization administered or previously received (G8482)


name: ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; HORMONE-REFRACTORY/ANDROGEN-INDEPENDENT (E.G., RISING PSA ON ANTI-ANDROGEN THERAPY OR POST-ORCHIECTOMY); CLINICAL METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-responsive; clinical metastases or m1 at diagnosis (for use in a medicare-approved demonstration project)


name: ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; STAGE I, II AT DIAGNOSIS, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; STAGE III, IV, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, TRANSFORMED FROM ORIGINAL CELLULAR DIAGNOSIS TO A SECOND CELLULAR CLASSIFICATION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; RELAPSED/REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; DIAGNOSTIC EVALUATION, STAGE NOT DETERMINED, EVALUATION OF POSSIBLE RELAPSE OR NON-RESPONSE TO THERAPY, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: ONCOLOGY; DISEASE STATUS; CHRONIC MYELOGENOUS LEUKEMIA, LIMITED TO PHILADELPHIA CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)


name: Frontier extended stay clinic demonstration; for a patient stay in a clinic approved for the cms demonstration project; the following measures should be present: the stay must be equal to or greater than 4 hours; weather or other conditions must prevent transfer or the case falls into a category of monitoring and observation cases that are permitted by the rules of the demonstration; there is a maximum frontier extended stay clinic (fesc) visit of 48 hours, except in the case when weather or other conditions prevent transfer; payment is made on each period up to 4 hours, after the first 4 hours


name: Wrist hand finger orthosis, includes one or more nontorsion joint(s), turnbuckles, elastic bands/springs, may include soft interface material, straps, prefabricated, includes fitting and adjustment


name: Terminal device, hook, mechanical, voluntary opening, any material, any size, lined or unlined, pediatric


name: Terminal device, hook, mechanical, voluntary closing, any material, any size, lined or unlined, pediatric


name: Terminal device, hand, mechanical, voluntary opening, any material, any size, pediatric


name: Terminal device, hand, mechanical, voluntary closing, any material, any size, pediatric


name: Terminal device, hook or hand, heavy duty, mechanical, voluntary opening, any material, any size, lined or unlined


name: Terminal device, hook or hand, heavy duty, mechanical, voluntary closing, any material, any size, lined or unlined


name: Physician management of patient home care, standard monthly case rate (per 30 days)


name: Physician management of patient home care, hospice monthly case rate (per 30 days)


name: Physician management of patient home care, episodic care monthly case rate (per 30 days)


name: Physician visit at member's home, outside of a capitation arrangement


name: Nurse practitioner visit at member's home, outside of a capitation arrangement


name: Breast reconstruction with gluteal artery perforator (gap) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral


name: Breast reconstruction of a single breast with "stacked" deep inferior epigastric perforator (diep) flap(s) and/or gluteal artery perforator (gap) flap(s), including harvesting of the flap(s), microvascular transfer, closure of donor site(s) and shaping the flap into a breast, unilateral


name: Genetic testing for amyotrophic lateral sclerosis (als)


name: Administration of medication, other than oral and/or injectable, by a health care agency/professional, per visit


name: Astigmatism correcting function of intraocular lens


name: Performance measure reporting modifier-action not performed, reason not otherwise specified


name: Tissue marker, implantable, any type, each


name: Continent device, stoma absorptive cover for continent stoma


name: Adhesive bandage, first-aid type, any size, each


name: COMBINATION ORAL/NASAL MASK, USED WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE, EACH


name: Oral cushion for combination oral/nasal mask, replacement only, each


name: Nasal pillows for combination oral/nasal mask, replacement only, pair


name: External ambulatory insulin delivery system, disposable, each, includes all supplies and accessories


name: Sensor; invasive (e.g., subcutaneous), disposable, for use with non-durable medical equipment interstitial continuous glucose monitoring system, one unit = 1 day supply


name: Transmitter; external, for use with non-durable medical equipment interstitial continuous glucose monitoring system


name: Receiver (monitor); external, for use with non-durable medical equipment interstitial continuous glucose monitoring system


name: Foot pressure off loading/supportive device, any type, each


name: Injection, gadoteridol, (prohance multipack), per ml


name: Injection, gadobenate dimeglumine (multihance), per ml


name: Injection, gadobenate dimeglumine (multihance multipack), per ml


name: Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml


name: Gastrostomy/jejunostomy tube, standard, any material, any type, each


name: Gastrostomy/jejunostomy tube, low-profile, any material, any type, each


name: Comprehensive preoperative assessment performed for cataract surgery with intraocular lens (IOL) placement (includes assessment of all of the following components) (EC): Dilated fundus evaluation performed within 12 months prior to cataract surgery (2020F) Pre-surgical (cataract) axial length, corneal power measurement and method of intraocular lens power calculation documented (must be performed within 12 months prior to surgery) (3073F) Preoperative assessment of functional or medical indication(s) for surgery prior to the cataract surgery with intraocular lens placement (must be performed within 12 months prior to cataract surgery) (3325F)


name: Melanoma follow up completed (includes assessment of all of the following components) (ML): History obtained regarding new or changing moles (1050F) Complete physical skin exam performed (2029F) Patient counseled to perform a monthly self skin examination (5005F)


name: Elevated blood pressure plan of care documented (CKD)


name: Plan of care for elevated hemoglobin level documented for patient receiving Erythropoiesis-Stimulating Agent therapy (ESA) (CKD)


name: Planned chemotherapy regimen, including at a minimum: drug(s) prescribed, dose, and duration, documented prior to initiation of a new treatment regimen (ONC)


name: Radiation dose limits to normal tissues established prior to the initiation of a course of 3D conformal radiation for a minimum of 2 tissue/organ (ONC)


name: Plan of care to address pain documented (COA) (ONC)


name: Auricular or periauricular pain assessed (AOE)


name: GERD symptoms assessed after 12 months of therapy (GERD)


name: Initial evaluation for condition (HEP C) (EPI, DSP)


name: Subsequent evaluation for condition (HEP C) (EPI)


name: Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr)


name: Advance Care Planning discussed and documented in the medical record, patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan (DEM) (GER, Pall Cr)


name: Pain severity quantified; pain present (COA) (ONC)


name: Pain severity quantified; no pain present (COA) (ONC)


name: New episode for condition (NMA-No Measure Associated)


name: Tympanic membrane mobility assessed with pneumatic otoscopy or tympanometry (OME)


name: Patient has documented immunity to Hepatitis A (HEP-C)


name: Patient has documented immunity to Hepatitis B (HEP-C) (IBD)


name: RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)


name: Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)


name: Documentation that hearing test was performed within 6 months prior to tympanostomy tube insertion (OME)


name: pT category (primary tumor), pN category (regional lymph nodes), and histologic grade documented in pathology report (PATH)


name: Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)


name: Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)


name: Prostate-specific antigen (PSA), and primary tumor (T) stage, and Gleason score documented prior to initiation of treatment (PRCA)


name: Bone scan performed prior to initiation of treatment or at any time since diagnosis of prostate cancer (PRCA)


name: Bone scan not performed prior to initiation of treatment nor at any time since diagnosis of prostate cancer (PRCA)


name: Low risk of recurrence, prostate cancer (PRCA)


name: Intermediate risk of recurrence, prostate cancer (PRCA)


name: High risk of recurrence, prostate cancer (PRCA)


name: Prostate cancer risk of recurrence not determined or neither low, intermediate nor high (PRCA)


name: Serum levels of calcium, phosphorus, intact Parathyroid Hormone (PTH) and lipid profile ordered (CKD)


name: Hemoglobin level greater than or equal to 13 g/dL (CKD, ESRD)


name: Hemoglobin level 11 g/dL to 12.9 g/dL (CKD, ESRD)


name: Hemoglobin level less than 11 g/dL (CKD, ESRD)


name: Intraocular pressure (IOP) reduced by a value of greater than or equal to 15% from the pre-intervention level (EC)


name: Intraocular pressure (IOP) reduced by a value less than 15% from the pre-intervention level (EC)


name: Patient is D (Rh) negative and unsensitized (Pre-Cr)


name: Patient is D (Rh) positive or sensitized (Pre-Cr)


name: HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)


name: American Joint Committee on Cancer (AJCC) stage documented and reviewed (ONC)


name: Cancer stage documented in medical record as metastatic and reviewed (ONC)


name: Estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer (ONC)


name: Estrogen receptor (ER) and progesterone receptor (PR) negative breast cancer (ONC)


name: Pathology report confirming malignancy documented in the medical record and reviewed prior to the initiation of chemotherapy (ONC)


name: Pathology report confirming malignancy documented in the medical record and reviewed prior to the initiation of radiation therapy (onc)


name: 1 of the following diagnostic imaging studies ordered: chest x-ray, CT, Ultrasound, MRI, PET, or nuclear medicine scans (ML)


name: None of the following diagnostic imaging studies ordered: chest X-ray, CT, Ultrasound, MRI, PET, or nuclear medicine scans (ML)


name: Preoperative assessment of functional or medical indication(s) for surgery prior to the cataract surgery with intraocular lens placement (must be performed within 12 months prior to cataract surgery) (EC)


name: Topical preparations (including OTC) prescribed for acute otitis externa (AOE)


name: Systemic antimicrobial therapy prescribed (AOE)


name: Systemic antimicrobial therapy not prescribed (AOE)


name: Antihistamines or decongestants prescribed or recommended (OME)


name: Antihistamines or decongestants neither prescribed nor recommended (OME)


name: Systemic corticosteroids prescribed (OME)


name: Patient receiving antiviral treatment for Hepatitis C (HEP-C)


name: Patient did not start or is not receiving antiviral treatment for Hepatitis C during the measurement period (HEP-C)


name: Combination peginterferon and ribavirin therapy prescribed (HEP-C)


name: Hepatitis A vaccine series previously received (HEP-C)


name: Hepatitis B vaccine series previously received (HEP-C)


name: Patient counseled about risks of alcohol use (HEP-C)


name: Counseling regarding contraception received prior to initiation of antiviral treatment (HEP-C)


name: Patient counseling at a minimum on all of the following treatment options for clinically localized prostate cancer: active surveillance, and interstitial prostate brachytherapy, and external beam radiotherapy, and radical prostatectomy, provided prior to initiation of treatment (PRCA)


name: Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)


name: 3-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT) received (PRCA)


name: Head of bed elevation (30-45 degrees) on first ventilator day ordered (CRIT)


name: Patient receiving care in the intensive care unit (ICU) and receiving mechanical ventilation, 24 hours or less (CRIT)


name: Patient either not receiving care in the intensive care unit (ICU) OR not receiving mechanical ventilation OR receiving mechanical ventilation greater than 24 hours (CRIT)


name: Patient receiving erythropoiesis-stimulating agents (ESA) therapy (CKD)


name: Patient not receiving erythropoiesis-stimulating agents (ESA) therapy (CKD)


name: Counseling about the potential impact of glaucoma on visual functioning and quality of life, and importance of treatment adherence provided to patient and/or caregiver(s) (EC)


name: Best-corrected visual acuity of 20/40 or better (distance or near) achieved within the 90 days following cataract surgery (EC)


name: Counseling about value of protection from UV light and lack of proven efficacy of nutritional supplements in prevention or progression of cataract development provided to patient and/or caregiver(s) (NMA-No Measure Associated)


name: Counseling about the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of age-related macular degeneration (AMD) provided to patient and/or caregiver(s) (EC)


name: Anti-D immune globulin received between 26 and 30 weeks gestation (Pre-Cr)


name: Tamoxifen or aromatase inhibitor (AI) prescribed (ONC)


name: Adjuvant chemotherapy referred, prescribed, or previously received for Stage III colon cancer (ONC)


name: Conformal radiation therapy received (NMA-No Measure Associated)


name: Conformal radiation therapy not received (NMA-No Measure Associated)


name: Continuous (12-months) therapy with proton pump inhibitor (PPI) or histamine H2 receptor antagonist (H2RA) received (GERD)


name: No continuous (12-months) therapy with either proton pump inhibitor (PPI) or histamine H2 receptor antagonist (H2RA) received (GERD)


name: Disease modifying anti-rheumatic drug therapy prescribed or dispensed (RA)


name: Appropriate angiotensin converting enzyme (ACE)/angiotensin receptor blockers (ARB) therapeutic monitoring test ordered or performed (AM)


name: Appropriate digoxin therapeutic monitoring test ordered or performed (AM)


name: Appropriate diuretic therapeutic monitoring test ordered or performed (AM)


name: Appropriate anticonvulsant therapeutic monitoring test ordered or performed (AM)


name: External beam radiotherapy as primary therapy to prostate with or without nodal irradiation (PRCA)


name: External beam radiotherapy with or without nodal irradiation as adjuvant or salvage therapy for prostate cancer patient (PRCA)


name: Angiotensin converting enzyme (ACE) or angiotensin receptor blockers (ARB) medication therapy for 6 months or more (MM)


name: Digoxin medication therapy for 6 months or more (MM)


name: Diuretic medication therapy for 6 months or more (MM)


name: Anticonvulsant medication therapy for 6 months or more (MM)


name: Treatment summary report communicated to physician(s) or other qualified health care professional(s) managing continuing care and to the patient within 1 month of completing treatment (ONC)


name: Treatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)


name: All elements of maximal sterile barrier technique, hand hygiene, skin preparation and, if ultrasound is used, sterile ultrasound techniques followed (CRIT)


name: Patient information entered into a recall system that includes: target date for the next exam specified and a process to follow up with patients regarding missed or unscheduled appointments (ML)


name: Excision of rectal tumor, transanal endoscopic microsurgical approach (ie, TEMS), including muscularis propria (ie, full thickness)


name: Brachytherapy source, stranded, iodine-125, per source


name: Brachytherapy source, non-stranded, iodine-125, per source


name: Brachytherapy source, stranded, palladium-103, per source


name: Brachytherapy source, non-stranded, palladium-103, per source


name: Brachytherapy source, stranded, cesium-131, per source


name: Brachytherapy source, non-stranded, cesium-131, per source


name: Brachytherapy source, stranded, not otherwise specified, per source


name: Brachytherapy source, non-stranded, not otherwise specified, per source


name: Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete


name: Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study


name: Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography


name: Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study


name: Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report


name: Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report


name: Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis


name: Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report


name: Microporous collagen implantable tube (neuragen nerve guide), per centimeter length


name: Microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length


name: Placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), for other than the following sites (any approach): abdomen, pelvis, prostate, retroperitoneum, thorax, single or multiple


name: Erythropoietic stimulating agent (esa) administered to treat anemia due to anti-cancer chemotherapy


name: Erythropoietic stimulating agent (esa) administered to treat anemia due to anti-cancer radiotherapy


name: Erythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapy


name: HEMATOCRIT LEVEL HAS EXCEEDED 39% (OR HEMOGLOBIN LEVEL HAS EXCEEDED 13.0 G/DL) FOR 3 OR MORE CONSECUTIVE BILLING CYCLES IMMEDIATELY PRIOR TO AND INCLUDING THE CURRENT CYCLE


name: HEMATOCRIT LEVEL HAS NOT EXCEEDED 39% (OR HEMOGLOBIN LEVEL HAS NOT EXCEEDED 13.0 G/DL) FOR 3 OR MORE CONSECUTIVE BILLING CYCLES IMMEDIATELY PRIOR TO AND INCLUDING THE CURRENT CYCLE


name: Partial credit received for replaced device


name: Dmepos item subject to dmepos competitive bidding program number 1


name: Dmepos item subject to dmepos competitive bidding program number 2


name: Beneficiary resides in a competitive bidding area and travels outside that competitive bidding area and receives a competitive bid item


name: Dmepos item subject to dmepos competitive bidding program number 3


name: Dmepos item subject to dmepos competitive bidding program that is furnished as part of a professional service


name: Dmepos item subject to dmepos competitive bidding program number 4


name: Dmepos item subject to dmepos competitive bidding program number 5


name: Investigational clinical service provided in a clinical research study that is in an approved clinical research study


name: Routine clinical service provided in a clinical research study that is in an approved clinical research study


name: Hospital bed, pediatric, manual, 360 degree side enclosures, top of headboard, footboard and side rails up to 24 inches above the spring, includes mattress


name: Hospital bed, pediatric, electric or semi-electric, 360 degree side enclosures, top of headboard, footboard and side rails up to 24 inches above the spring, includes mattress


name: Encounter for routine and ritual male circumcision


name: Encounter for fitting or adjustment of artificial eye


name: Tempo brand of antacid Reformulated Feb 2009


name: Type of activities in which resident is currently involved


name: Extent of resident involvement in activities


name: Number of D antidepressant medication received


name: Other current diagnoses & ICD9 codes (quarterly)


name: Outpatient encounter-level information section:-:Pt:^Patient:Set:HIV-ART


name: Antiretroviral therapy status section:-:Pt:^Patient:Set:HIV-ART


name: HIV care & family status section:-:Pt:^Patient:Set:HIV-ART


name: Number of hospital D since last outpatient visit:Num:Pt:^Patient:Qn:Reported


name: Number of hospital D since last outpatient visit


name: Evidence of tuberculosis resistance:Find:Pt:^Patient:Nom:Reported


name: human immunodeficiency virus confirmation facility


name: Institutional entry point HIV Rx:Type:Pt:Facility:Nom:Reported


name: Institutional entry point human immunodeficiency virus Rx


name: HIV Rx prior clinic transferred from:Addr:Pt:Facility:Nom:Reported


name: human immunodeficiency virus Rx prior clinic transferred from


name: HIV Rx prior clinic transferred from:ID:Pt:Facility:Nom:Reported


name: PHQ-9: quick depression assessment panel


name: District where patient entered HIV Rx:ID:Pt:^Patient:Nom:Reported


name: District where patient entered human immunodeficiency virus Rx


name: HIV Rx prior to enrollment:Type:Pt:^Patient:Nom:Reported


name: human immunodeficiency virus Rx prior to enrollment


name: Reason medically eligible for HIV Rx:Find:Pt:^Patient:Nom:Reported


name: Reason medically eligible for human immunodeficiency virus Rx


name: Date eligible and selected to start HIV Rx:Date:Pt:^Patient:Qn:Reported


name: Date eligible and selected to start HIV Rx


name: Date original clinic HIV Rx start:Date:Pt:^Patient:Qn:Reported


name: Date original clinic human immunodeficiency virus Rx start


name: Date lost to HIV Rx follow-up:Date:Pt:^Patient:Qn:Reported


name: Date lost to human immunodeficiency virus Rx follow-up


name: Date lost to HIV Rx therapy:Date:Pt:^Patient:Qn:Reported


name: Date lost to human immunodeficiency virus Rx therapy


name: Current HIV Rx therapy duration:Time:Pt:^Patient:Qn:Computed


name: Isoniazid therapy start date:Date:Pt:^Patient:Qn:Reported


name: Tuberculosis treatment start date:Date:Pt:^Patient:Qn:Reported


name: Reason for discontinuation of anti-infective phrophylaxis medication:Type:Pt:^Patient:Nom:Reported


name: Reason for discontinuation of anti-infective phrophylaxis medication


name: HIV ART medication dose number taken/Medication dose number prescribed:NFr:Pt:^Patient:Qn:Reported


name: HIV ART medication dose number taken/Medication dose number prescribed


name: Degree of adherence to co-trimoxazole:Find:Pt:^Patient:Ord:Reported


name: Degree of adherence to anti-retroviral drug regimen:Find:Pt:^Patient:Ord:Reported


name: Degree of adherence to anti-retroviral drug regimen


name: Reason for missing HIV Rx administration schedule:Find:Pt:^Patient:Nom:Reported


name: Reason for missing HIV Rx administration schedule


name: HIV Rx clinic transferred to:Addr:Pt:Facility:Nom:Reported


name: human immunodeficiency virus Rx clinic transferred to


name: HIV Rx clinic transferred to:ID:Pt:Facility:Nom:Reported


name: Date dropped from HIV Rx:Date:Pt:^Patient:Qn:Reported


name: Date dropped from human immunodeficiency virus Rx


name: HIV ART medication dose number taken/Medication dose number prescribed:NFr:Pt:^Patient:Qn:MEMS Cap


name: HIV ART actual prescription fills number/Ideal prescription fills number:NFr:Pt:^Patient:Qn:Pharmacy records


name: HIV ART actual prescription fills number/Ideal prescription fills number


name: human immunodeficiency virus ART medication


name: {HIV ART medication} doses missed yesterday:Num:Pt:^Patient:Qn:Reported.ACTG


name: {HIV ART medication} doses missed yesterday


name: {HIV ART medication} doses missed 2D ago:Num:Pt:^Patient:Qn:Reported.ACTG


name: {HIV ART medication} doses missed 2D ago


name: {HIV ART medication} doses missed 3D ago:Num:Pt:^Patient:Qn:Reported.ACTG


name: {HIV ART medication} doses missed 3D ago


name: {HIV ART medication} doses missed 4D ago:Num:Pt:^Patient:Qn:Reported.ACTG


name: {HIV ART medication} doses missed 4D ago


name: Codes for assessments required for Medicare PPS or the State


name: Daily contact with relatives &or close friends


name: Unknown customary routine - resident &or family unable to provide information


name: Date of last day of MDS observation period


name: Medicaid resident liability or Medicare copayment


name: Advance directive - medication restrictions


name: Advance directive - other treatment restrictions


name: Memory &or recall - none of above are recalled


name: Cognitive skills for daily decision making


name: Mental function varies over the course of the day


name: Uses written messages to express or clarify needs


name: Resident perceives that daily routine (customary routine, activities) is very different from prior pattern in the community


name: Conditions &or diseases make resident's cognitive, ADL, mood or behavior patterns unstable


name: Resident experiencing an acute episode or a flare-up of a recurrent or chronic problem


name: End-Stage disease, 6 or fewer Mo to live


name: Expression of what appear to be unrealistic fears


name: Recurrent statements that something terrible is about to happen


name: Balance while sitting - position, trunk control


name: Other limitation or loss - range of motion


name: Other limitation or loss - voluntary movement


name: Bed rails used for bed mobility or transfer


name: Frequency of verbally abusive behavioral symptoms


name: Alterability of verbally abusive behavioral symptoms


name: Frequency of physically abusive behavioral symptoms


name: Alterability of physically abusive behavioral symptoms


name: Frequency of socially inappropriate or disruptive behavioral symptoms


name: Alterability of socially inappropriate or disruptive behavioral symptoms


name: Unhappy with residents other than roommate


name: Openly expresses conflict &or anger with family &or friends


name: Absence of contact with family &or friends


name: Recent loss of close family member &or friend


name: Does not adjust easily to change in routines


name: Expresses sadness &or anger &or empty feeling over lost roles &or status


name: Resident believes he or she is capable of increased independence in at least some ADLs


name: Direct care staff believe resident is capable of increased independence in at least some ADLs


name: Resident able to perform tasks or activity but is very slow


name: Difference in ADL Self-Performance or ADL Support, comparing mornings to evenings


name: Bowel elimination pattern regular - at least one movement every three D


name: Did not use toilet room &or commode &or urinal


name: Other current or more detailed diagnoses & ICD9 codes


name: Insufficient fluid; did NOT consume all or almost all liquids provided during last 3D


name: Regular or repetitive complaints of hunger


name: Plate guard, stabilized built-up utensil, etc.


name: Training in skills required to return to the community


name: Debris - soft, easily movable substances - present in mouth prior to going to bed at night


name: Inflamed, swollen, or bleeding gums, oral abscesses; ulcers or rashes


name: Daily cleaning of teeth or dentures or mouth care by resident or staff


name: Nutrition or hydration intervention to manage skin problems


name: Application of dressings (with or without topical medications) other than to feet


name: Application of ointments or medications other than to feet


name: Other preventative or protective skin care other than to feet


name: Nails &or calluses trimmed during last 90D


name: Application of dressings (foot) - with or without topical medications


name: Special behavior symptom evaluation program


name: Evaluation by a licensed mental health specialist in last 90D


name: Resident-specific deliberate changes in the environment to address mood &or behavior patterns


name: Number of D of splint or brace assistance


name: Number of D of training & skill practice in bed mobility


name: Number of D of training & skill practice in transfer


name: Number of D of training & skill practice in walking


name: Number of D of training & skill practice in dressing or grooming


name: Number of D of training & skill practice in eating or swallowing


name: Number of D of training & skill practice in amputation or prosthesis care


name: Number of D of training & skill practice in communication


name: Bed rails - full bed rails on all open sides of bed


name: Bed rails - other types of side rails used


name: Resident expresses &or indicates preference to return to the community


name: Resident has a support person who is positive towards discharge


name: Stay projected to be of a short duration - discharge projected within 90D


name: Through D 15, provide an estimate of the number of D when at least 1 therapy service can be expected to have been delivered


name: Through day 15, provide an estimate of the number of therapy minutes (across the therapies) that can be expected to be delivered


name: Furthest distance walked without sitting down during this episode


name: Time walked without sitting down during this episode


name: Self-Performance in walking during this episode


name: Parallel bars used by resident in association with this episode


name: Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda.free:MRto:24H:Urine:Qn


name: Beta F1 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Papova virus SV40 DNA:NCnc:Pt:Stool:Qn:Probe.amp.tar


name: Parvovirus B19 DNA:NCnc:Pt:Amnio fld:Qn:Probe.amp.tar


name: Parvovirus B19 DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Aspergillus sp Ab:PrThr:Pt:CSF:Ord:Immune diffusion


name: Herpes simplex virus 1+2 Ab.IgM:Titr:Pt:CSF:SemiQn:IF


name: 11-Dehydro thromboxane beta 2/Creatinine:MRto:Pt:Urine:Qn


name: FBN1 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Reason for stopping HIV Rx:Type:Pt:^Patient:Nom:Reported


name: Date determined medically eligible to start HIV Rx:Date:Pt:^Patient:Qn:Reported


name: Date determined medically eligible and ready to start HIV Rx:Date:Pt:^Patient:Qn:Reported


name: Medication or other side effects associated with HIV Rx:Type:Pt:^Patient:Nom:Reported


name: Severity of side effect to HIV Rx:Type:Pt:^Patient:Nom:Reported


name: Symptom, diagnosis, or opportunistic infection related to HIV Rx:Type:Pt:^Patient:Nom:Reported


name: 11-Deoxycortisol^2H post dose metyraPONE:MCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxypregnenolone^1H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Aldosterone^2H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Muscle sarcolemma Ab:Titr:Pt:Plr fld:SemiQn:IF


name: ATN1 gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: ATN1 gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: FXN gene allele 1.GAA repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: FXN gene allele 2.GAA repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: HTT gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: HTT gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: Lymphocyte proliferation.100 umol beryllium stimulation^6D post incubation:Ratio:Pt:Bld:Qn


name: Arterial-mixed venous oxygen saturation difference:MFr:Pt:Bld:Qn


name: Arterial-mixed venous oxygen saturation difference


name: Arterial-venous oxygen saturation difference:MFr:Pt:Bld:Qn


name: Arterial-venous oxygen saturation difference


name: Iron & Iron binding capacity panel:-:Pt:Ser/Plas:Qn


name: Cholesterol.in IDL+Cholesterol.in VLDL 3:MCnc:Pt:Ser/Plas:Qn


name: Varicella zoster virus DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Varicella zoster virus DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Varicella zoster virus DNA:NCnc:Pt:Amnio fld:Qn:Probe.amp.tar


name: Varicella zoster virus DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: Alpha synuclein Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Androgen receptor Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Annexin 1 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Alzheimer precursor protein Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Beta catenin Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: IgG subclass 4 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Cyclooxygenase 2 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Herpes virus 8 latent nuclear Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Vascular endothelial growth factor Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Glucose tolerance^post 75 g glucose PO:Imp:Pt:Ser/Plas:Nar


name: Glucose tolerance^post 100 g glucose PO:Imp:Pt:Ser/Plas:Nar


name: Hepatitis E virus Ab.IgG:PrThr:Pt:Ser:Ord:IA


name: Carbon dioxide^^adjusted to patient's actual temperature:PPres:Pt:BldCoA:Qn


name: Carbon dioxide^^adjusted to patient's actual temperature:PPres:Pt:BldCoV:Qn


name: Oxygen^^adjusted to patient's actual temperature:PPres:Pt:BldCoA:Qn


name: Oxygen^^adjusted to patient's actual temperature:PPres:Pt:BldCoV:Qn


name: pH^^adjusted to patient's actual temperature:LsCnc:Pt:BldCoA:SemiQn


name: pH^^adjusted to patient's actual temperature:LsCnc:Pt:BldCoV:SemiQn


name: Neural tube defect risk:Likelihood:Pt:^Population:Qn


name: Coagulation:Time:Pt:PPP:Qn:Coag.surface induced.factor substitution.2H post incubation after 1:4 addition of normal plasma


name: Coagulation:Time:Pt:PPP:Qn:Coag.surface induced.factor substitution.1H post incubation after 1:4 addition of normal plasma


name: Coagulation:Time:Pt:PPP:Qn:Coag.surface induced.factor substitution.after addition of normal plasma 1H post incubation separate tubes


name: Hepatitis C virus core Ag:PrThr:Pt:Bld/Bone mar^Donor:Ord


name: Herpes simplex virus 1+2 Ab.IgG:PrThr:Pt:Ser:Ord:IB


name: Snowshoe hare virus Ab.Neut:PrThr:Pt:XXX:Ord:Neut


name: Advanced oxidation protein products:SCnc:Pt:Ser/Plas:Qn


name: Basal metabolic rate index:ACnc:Pt:^Patient:Qn


name: Glomerular filtration rate:ArVRat:Pt:Ser/Plas/Bld:Qn:Creatinine-based formula (MDRD)/1.73 sq M among female population


name: Glomerular basement membrane Ab:ACnc:Pt:Ser:Qn


name: Transforming growth factor beta 1:MCnc:Pt:Ser/Plas:Qn


name: COL5A1 gene+COL5A2 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: SMN1 gene+SMN2 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: (Arachis hypogaea+Bean white+Glycine max+Lens esculenta+Pisum sativum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: Mahogany wood dust Ab.IgE:ACnc:Pt:Ser:Qn


name: Colorado tick fever virus Ab.Neut:PrThr:Pt:XXX:Ord:Neut


name: Calcitonin Calcium & Pentagastrin challenge panel:-:Pt:Ser/Plas:Qn


name: Calcitonin Calcium & Pentagastrin challenge panel


name: Calcitonin^10M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV:MCnc:Pt:Ser/Plas:Qn


name: Calcitonin^5M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV:MCnc:Pt:Ser/Plas:Qn


name: Calcitonin^2M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV:MCnc:Pt:Ser/Plas:Qn


name: Calcitonin^1M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV:MCnc:Pt:Ser/Plas:Qn


name: Calcitonin^pre 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV:MCnc:Pt:Ser/Plas:Qn


name: Influenza virus A Ab.Neut:Prid:Pt:Ser:Nom:Neut


name: Influenza virus A Ag:Prid:Pt:Isolate:Nom


name: Influenza virus A.adamantane resistance:PrThr:Pt:Isolate:Ord:Phenotyping


name: Influenza virus A.adamantane resistance:PrThr:Pt:Isolate:Ord


name: Influenza virus A.adamantane resistant RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus A H1 Ag:PrThr:Pt:Isolate:Ord:IF


name: Influenza virus A matrix protein RNA:PrThr:Pt:Isolate:Ord:Sequencing


name: Referral lab test identifier and name:ID:Pt:Referral lab test:Nom


name: Trisomy 18 risk cutoff:Find:Pt:^Fetus:Qn


name: Trisomy 21 risk cutoff:Find:Pt:^Fetus:Qn


name: Neural tube defect risk cutoff:Find:Pt:^Fetus:Qn


name: Protein C/Coagulation factor X:MRto:Pt:PPP:Qn


name: Protein S Ag/Coagulation factor X Ag:MRto:Pt:PPP:Qn:Coag


name: SCA1 gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SCA1 gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SCA10 gene allele 1.ATTCT repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SCA10 gene allele 2.ATTCT repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SCA2 gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SOD1 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Listeria sp Ab:Titr:Pt:Ser:SemiQn:Comp fix


name: Parainfluenza virus Ab:Titr:Pt:Ser:SemiQn:Comp fix


name: t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points:Arb:Pt:Bone mar:Ord:Molgen


name: t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points:Arb:Pt:Bone mar:Ord:Molgen


name: t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript:Arb:Pt:Bld/Tiss:Ord:Molgen


name: t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript:NCnc:Pt:Bld/Tiss:Qn:Molgen


name: t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript:PrThr:Pt:Bone mar:Ord:Molgen


name: Androstenedione^1H post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Renin^3H post XXX challenge:CCnc:Pt:Plas:Qn


name: Renin^2H post XXX challenge:CCnc:Pt:Plas:Qn


name: Vasopressin^30M post XXX challenge:MCnc:Pt:Plas:Qn


name: BK virus DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Epstein Barr virus DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Epstein Barr virus DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Epstein Barr virus DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: Epstein Barr virus DNA:NCnc:Pt:Amnio fld:Qn:Probe.amp.tar


name: Epstein Barr virus DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:ACnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:ACnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LnCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:ACnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LnCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LnCnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LnCnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:ACnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LnCnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LnCnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LnCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LnCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:ACnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:ACnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:ACnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:ACnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Herpes simplex virus 1+2 DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Herpes simplex virus 1+2 DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Herpes simplex virus 1+2 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Herpes simplex virus 1+2 DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Herpes simplex virus 1+2 DNA:NCnc:Pt:Amnio fld:Qn:Probe.amp.tar


name: Herpes simplex virus 1+2 DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Herpes virus 6 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Herpes virus 7 DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Herpes virus 8 DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: JC virus DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:BAL:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Papova virus SV40 DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Pneumocystis jirovecii DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Toxoplasma gondii DNA:NCnc:Pt:Amnio fld:Qn:Probe.amp.tar


name: Toxoplasma gondii DNA:NCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Varicella zoster virus DNA:NCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Varicella zoster virus DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar


name: Platelet aggregation:RelACnc:Pt:PRP:Qn:Aggregometry.ristocetin induced.1800 ug/mL


name: Microbiology section:-:-:^FDA package insert:Nar


name: BCR-ABL1 b2a2 fusion protein:PrThr:Pt:Bld/Tiss:Ord:Molgen


name: BCR-ABL1 b3a2 fusion protein:PrThr:Pt:Bld/Tiss:Ord:Molgen


name: Hepatitis B virus surface Ab Actual/Negative control:RelACnc:Pt:Ser/Plas:Qn


name: Hepatitis B virus surface Ab Actual/Negative control


name: BCR-ABL1 e1a1 fusion protein:PrThr:Pt:Bld/Tiss:Ord:Molgen


name: Calcium oxalate dihydrate/Total:MFr:Pt:Calculus:Qn:Infrared spectroscopy


name: Calcium oxalate monohydrate/Total:MFr:Pt:Calculus:Qn:Infrared spectroscopy


name: CMT demyelinating gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Erythrocyte clumps:Naric:Pt:Urine sed:Qn:Automated count


name: MYOC gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: View^W contrast intra duct:Find:Pt:Breast>Breast duct.right:Doc:MG


name: View^W contrast intra duct:Find:Pt:Breast>Breast duct.left:Doc:MG


name: View runoff^WO & W contrast IA:Find:Pt:Lower extremity>Femoral artery:Doc:RF.angio


name: Influenza virus A H16 Ab:Titr:Pt:Ser:SemiQn:HAI


name: Influenza virus A H1 RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus A H1 RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Influenza virus A H3 Ag:PrThr:Pt:Isolate:Ord:IF


name: Influenza virus A H3 RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus A H3 RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Influenza virus A H5 Ab:PrThr:Pt:Ser:Ord


name: Influenza virus A H5 RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus A H7 RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus A H9 RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Influenza virus A Ag:PrThr:Pt:Isolate:Ord:IF


name: Influenza virus A RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus A hemagglutinin type RNA:Prid:Pt:Isolate:Nom:Sequencing


name: Influenza virus B Ab:PrThr:Pt:Ser:Ord:IA


name: Influenza virus B Ag:PrThr:Pt:Isolate:Ord:IF


name: Influenza virus B RNA:PrThr:Pt:Isolate:Ord:Probe.amp.tar


name: Influenza virus B RNA:Prid:Pt:Isolate:Nom:Sequencing


name: Influenza virus A & B RNA:Prid:Pt:Isolate:Nom:Probe.amp.tar


name: Influenza virus:Prid:Pt:XXX:Nom:Shell vial culture


name: Date and time of pheresis procedure:TmStp:Pt:^Patient:Qn


name: Newborn screening recommended follow-up:Imp:Pt:^Patient:Nom


name: Date referral lab test sent:TmStp:XXX:Referral lab test:Qn


name: Referral lab test method:Type:Pt:Referral lab test:Nar


name: Holoprosencephaly gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Troponin I.cardiac:MCnc:Pt:Ser/Plas:Qn:Detection limit <= 0.01 ng/mL


name: Epstein Barr virus band pattern:Imp:Pt:XXX:Nar:IB


name: Multisection^at rest+W Tc-99m Sestamibi IV:Find:Pt:Chest>Heart:Doc:NM.SPECT


name: Multisection perfusion^W adenosine+W Tc-99m Sestamibi IV:Find:Pt:Chest>Heart:Doc:NM.SPECT


name: Multisection perfusion^at rest+W stress+W Tl-201 IV+W Tc-99m Sestamibi IV:Find:Pt:Chest>Heart:Doc:NM.SPECT


name: Multisection perfusion+wall motion^at rest+W stress+W Tl-201 IV+W Tc-99m Sestamibi IV:Find:Pt:Chest>Heart:Doc:NM.SPECT


name: Views GE 6:Find:Pt:Lower extremity.bilateral>Ankle:Doc:XR


name: Views limited^W I-131 MIBG IV:Find:Pt:XXX:Doc:NM


name: Second trimester triple maternal screen:Imp:Pt:Ser/Plas:Nar


name: Alpha-1-Fetoprotein multiple of the median cutoff:MoM:Pt:Ser/Plas:Qn


name: Alpha-1-Fetoprotein multiple of the median cutoff


name: First & Second trimester integrated maternal screen:Imp:Pt:^Patient:Nom


name: First trimester maternal screen with nuchal translucency:Imp:Pt:^Patient:Nar


name: Bacterial susceptibility panel:-:Pt:Isolate:OrdQn:Gradient strip


name: Calcidiol & Calciferol panel:-:Pt:Ser/Plas:-


name: Hepatitis B virus DNA:LaCnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LaCnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LaCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LaCnc:Pt:CSF:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LaCnc:Pt:Bone mar:Qn:Probe.amp.tar


name: Hepatitis C virus RNA:LaCnc:Pt:XXX:Qn:Probe.amp.tar


name: Hepatitis B virus DNA:LaCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Hepatitis C virus genotype:Prid:Pt:Tiss:Nom:Probe.amp.tar


name: Hepatitis C virus RNA:LaCnc:Pt:Tiss:Qn:Probe.amp.tar


name: Bacterial carbapenem resistance blaKPC gene:PrThr:Pt:Isolate/Specimen:Ord:Molgen


name: SCA2 gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: MJD gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: MJD gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: CACNA1A gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: CACNA1A gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SCA7 gene allele 1.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: SCA7 gene allele 2.CAG repeats:EntNum:Pt:Bld/Tiss:Qn:Molgen


name: HIV protease gene mutations:-:Pt:Isolate:-:Genotyping


name: HIV nonnucleoside reverse transcriptase susceptibility panel:-:Pt:Isolate:-:Genotyping


name: HIV nonnucleoside reverse transcriptase susceptibility panel


name: HIV nucleoside reverse transcriptase susceptibility panel:-:Pt:Isolate:-:Genotyping


name: HIV nucleoside reverse transcriptase susceptibility panel


name: HIV reverse transcriptase susceptibility panel:-:Pt:Isolate:-:Genotyping


name: HIV reverse transcriptase susceptibility panel


name: HIV protease gene mutations:-:Pt:Isolate:-:Phenotyping


name: HIV nonnucleoside reverse transcriptase susceptibility panel:-:Pt:Isolate:-:Phenotyping


name: HIV nucleoside reverse transcriptase susceptibility panel:-:Pt:Isolate:-:Phenotyping


name: HIV reverse transcriptase susceptibility panel:-:Pt:Isolate:-:Phenotyping


name: Lymphocyte proliferation.100 umol beryllium stimulation^7D post incubation:Ratio:Pt:Bld:Qn


name: Lymphocyte proliferation.10 umol beryllium stimulation^5D post incubation:Ratio:Pt:Bld:Qn


name: Lymphocyte proliferation.10 umol beryllium stimulation


name: Lymphocyte proliferation.10 umol beryllium stimulation^7D post incubation:ACnc:Pt:Bld:Qn


name: Lymphocyte proliferation.1 umol beryllium stimulation^5D post incubation:Ratio:Pt:Bld:Qn


name: Lymphocyte proliferation.1 umol beryllium stimulation


name: Lymphocyte proliferation.1 umol beryllium stimulation^7D post incubation:Ratio:Pt:Bld:Qn


name: CPT2 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Lymphocyte proliferation.phytohemagglutinin stimulation^3D post incubation:Ratio:Pt:Bld:Qn


name: ERBB2 gene copy number/Chromosome 17 copy number:NRto:Pt:Tiss:Qn:FISH


name: pH^^adjusted to patient's actual temperature:LsCnc:Pt:Bld:SemiQn


name: SH3TC2 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: LMNA gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: ARSA gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: KCNQ2 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: TTR gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Deprecated Epithelial cells.squamous [Presence] in Urine sediment by Light microscopy


name: Hepatitis C virus RNA:ACnc:Pt:Ser/Plas:Qn:Probe.amp.tar detection limit = 5 IU/mL


name: Hepatitis D virus Ab.IgG:ACnc:Pt:Ser:Qn:IA


name: Coagulation factor VII Ag actual/Normal:RelACnc:Pt:PPP:Qn:IA


name: FH gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: POU3F4 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: ABCB4 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hydrogen/Expired gas^1.5H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^2H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^3H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Fetal lung maturity panel:-:Pt:Amnio fld:Qn


name: Cytokeratin 19 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Cytokeratin 5 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Galectin 3 Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Granzyme B Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Helicobacter pylori Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: Hepatocyte paraffin 1 Ab:PrThr:Pt:Tiss:Ord:Immune stain


name: Serotonin release.heparin.low molecular weight interpretation:Imp:Pt:Ser:Nom


name: Serotonin release.heparin.low molecular weight interpretation


name: Serotonin release.heparin.low molecular weight panel:-:Pt:Ser:-


name: Serotonin release.heparin.low molecular weight panel


name: Serotonin release.heparin.porcine & low molecular weight panel:-:Pt:Ser:-


name: Serotonin release.heparin.porcine & low molecular weight panel


name: Guaranteed analysis of feed section:-:-:^FDA product label:Nar


name: Horowitz index^^adjusted to patient's actual temperature:Ratio:Pt:BldC+Inhl gas:Qn


name: Horowitz index^^adjusted to patient's actual temperature:Ratio:Pt:BldA+Inhl gas:Qn


name: Horowitz index^^adjusted to patient's actual temperature:Ratio:Pt:BldMV+Inhl gas:Qn


name: Horowitz index^^adjusted to patient's actual temperature:Ratio:Pt:BldV+Inhl gas:Qn


name: CMT demyelinating gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Taenia solium larva Ab:ACnc:Pt:CSF:Qn:IA


name: 2-Hydroxyestrone & 16-Alpha hydroxyestrone panel:-:Pt:Ser/Plas:-


name: 2-Hydroxyestrone & 16-Alpha hydroxyestrone panel


name: Protein fractions.oligoclonal bands:Num:Pt:CSF:Qn:Isoelectric focusing


name: G6PC gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Coagulation factor VIII activity actual/Normal:RelACnc:Pt:PPP:Qn:Chromo


name: Herpes simplex virus 1 DNA:NCnc:Pt:Body fld:Qn:Probe.amp.tar


name: Herpes simplex virus 1 DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Herpes simplex virus 2 DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar


name: Herpes simplex virus 2 DNA:NCnc:Pt:Body fld:Qn:Probe.amp.tar


name: Herpes simplex virus 2 DNA:NCnc:Pt:CSF:Qn:Probe.amp.tar


name: Borrelia burgdorferi 18_20kD Ab.IgG:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 18_20kD Ab.IgG:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 18_20kD Ab.IgM:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 18_20kD Ab.IgM:PrThr:Pt:Ser:Ord:IB


name: Hepatitis B virus codon 173:Prid:Pt:Isolate:Nom:Genotyping


name: Hepatitis B virus codon 180:Prid:Pt:Isolate:Nom:Genotyping


name: Hepatitis B virus codon 181:Prid:Pt:Isolate:Nom:Genotyping


name: Hepatitis B virus codon 204:Prid:Pt:Isolate:Nom:Genotyping


name: Hepatitis B virus codon 236:Prid:Pt:Isolate:Nom:Genotyping


name: Hepatitis B virus codon 80:Prid:Pt:Isolate:Nom:Genotyping


name: Hepatitis B virus resistance panel:-:Pt:Isolate:-:Genotyping


name: Lymphocyte proliferation.tetanus toxoid stimulation^7D post incubation:Ratio:Pt:Bld:Qn


name: Lymphocyte proliferation.beryllium stimulation panel:-:Pt:Bld:-


name: Lymphocyte proliferation.beryllium stimulation panel


name: Adenosine monophosphate.cyclic/Creatinine^1st specimen post XXX challenge:Ratio:Pt:Urine:Qn


name: Dehydroepiandrosterone^1st specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Dehydroepiandrosterone sulfate^1H post dose corticotropin:MCnc:Pt:Ser/Plas:Qn


name: Dehydroepiandrosterone sulfate^pre dose corticotropin:MCnc:Pt:Ser/Plas:Qn


name: Human papilloma virus DNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Somatotropin^1st specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Somatotropin^7th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Somatotropin^9th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Somatotropin^10th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Histoplasma capsulatum M Ab:PrThr:Pt:CSF:Ord


name: Immunoglobulin light chains.kappa/Immunoglobulin light chains.lambda:MRto:24H:Urine:Qn


name: Japanese encephalitis virus Ab:Titr:Pt:CSF:SemiQn


name: Legionella pneumophila 1+2+3+4+5+6 Ab.IgM:PrThr:Pt:Ser:Ord


name: Lymphocyte proliferation.10 umol beryllium stimulation^6D post incubation:Ratio:Pt:WBC:Qn


name: Lymphocyte proliferation.concanavalin A stimulation:NRat:Pt:Bld:Qn


name: Lymphocyte proliferation.concanavalin A stimulation


name: Lymphocyte proliferation.pokeweed mitogen stimulation:NRat:Pt:Bld:Qn


name: Lymphocyte proliferation.pokeweed mitogen stimulation


name: Glucose-6-Phosphate dehydrogenase:CCnt:Pt:RBC:Qn:Glock & McLean


name: Serum/Plasma+Pleural fluid (thoracentesis fld)


name: Lactate dehydrogenase.plr fld/Lactate dehydrogenase.serum:RelRto:Pt:Ser/Plas+Plr fld:Qn


name: Observation:SpGrav:Pt:Urine:Qn:Adjustment to pH 7.4


name: Urate renal clearance/1.73 sq M:ArVRat:XXX:Urine+Ser/Plas:Qn


name: Cortisol^1H post 250 ug corticotropin IM:SCncDiff:Pt:Ser/Plas:Qn


name: Cortisol^30M post 250 ug corticotropin IM:SCncDiff:Pt:Ser/Plas:Qn


name: Borrelia burgdorferi 31kD Ab.IgG:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 31kD Ab.IgM:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 34kD Ab.IgG:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 34kD Ab.IgM:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 35kD Ab.IgG:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 35kD Ab.IgG:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 35kD Ab.IgM:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 35kD Ab.IgM:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 37kD Ab.IgG:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 37kD Ab.IgG:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 37kD Ab.IgM:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 37kD Ab.IgM:PrThr:Pt:CSF:Ord:IB


name: Herpes simplex virus 1 DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar


name: Borrelia burgdorferi 83_93kD Ab.IgG:PrThr:Pt:CSF:Ord:IB


name: Borrelia burgdorferi 83_93kD Ab.IgG:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 83_93kD Ab.IgM:PrThr:Pt:Ser:Ord:IB


name: Borrelia burgdorferi 83_93kD Ab.IgM:PrThr:Pt:CSF:Ord:IB


name: Platelet aggregation interpretation:Imp:Pt:PRP:Nom:Collagen induced


name: Hydrogen/Expired gas^30M post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^1H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Indirect antiglobulin test.polyspecific reagent:PrThr:Pt:Ser/Plas:Ord:PEG


name: Hydrogen/Expired gas^2.5H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: West Nile virus Ag:PrThr:Pt:Bld/Bone mar^Donor:Ord


name: Hepatitis C virus RNA panel:-:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Fractional excretion of phosphate:Ratio:XXX:Urine+Ser/Plas:Qn


name: Fatty acids.very long chain.C24:0/Creatinine:SRto:Pt:Urine:Qn


name: Fatty acids.very long chain.C24:0/Creatinine


name: Urea renal clearance/1.73 sq M:ArVRat:XXX:Urine+Ser/Plas:Qn


name: 11-Hydroxyandrostenedione^pre 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Hydroxyandrostenedione^30M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Hydroxyandrostenedione^1H post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^pre 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^30M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^45M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^1H post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 17-Ketosteroids^2D post dose dexamethasone:MCnc:Pt:Urine:Qn


name: 17-Hydroxypregnenolone^pre 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxypregnenolone^1H post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 17-Hydroxyprogesterone^pre 250 ug corticotropin IM:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycortisol^45M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycortisol^pre 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycortisol^30M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: 21-Deoxycortisol^1H post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Adenine phosphoribosyltransferase:CCnt:Pt:Amnio fld cells:Qn


name: Aldosterone^pre 250 ug corticotropin IM:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^30M post 250 ug corticotropin IM:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^1H post 250 ug corticotropin IM:SCnc:Pt:Ser/Plas:Qn


name: t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript:LnRto:Pt:Bld/Tiss:Qn:Molgen


name: Glomerular filtration rate:ArVRat:Pt:Ser/Plas/Bld:Qn:Cystatin C-based formula/1.73 sq M


name: Respiratory pathogens DNA & RNA 12a panel:-:Pt:XXX:-:Probe.amp.tar


name: Collection interval from baseline:Time:Pt:^Specimen:Qn


name: Oval fat bodies (globules):PrThr:Pt:Urine:Ord:Computer assisted


name: Leukocyte clumps:Naric:Pt:Urine sed:Qn:Automated count


name: Mixed cellular casts:PrThr:Pt:Urine:Ord:Computer assisted


name: 17-Ketosteroids^post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Ketosteroids^2D post high dose dexamethasone:MCnc:24H:Urine:Qn


name: 17-Ketosteroids^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 17-Hydroxycorticosteroids^post high dose dexamethasone:MRat:24H:Urine:Qn


name: 17-Hydroxycorticosteroids^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 17-Hydroxycorticosteroids^2D post dose dexamethasone:MRat:24H:Urine:Qn


name: 17-Hydroxypregnenolone^30M post 250 ug corticotropin:SCnc:Pt:Ser/Plas:Qn


name: Fatty acids.nonesterified^1st specimen post CFst:SCnc:Pt:Ser/Plas:Qn


name: Fatty acids.nonesterified^2nd specimen post CFst:SCnc:Pt:Ser/Plas:Qn


name: Fatty acids.nonesterified^3rd specimen post CFst:SCnc:Pt:Ser/Plas:Qn


name: Fatty acids.nonesterified^4th specimen post CFst:SCnc:Pt:Ser/Plas:Qn


name: Fatty acids.nonesterified^5th specimen post CFst:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^post 25 mg captopril PO:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^pre 25 mg captopril PO:SCnc:Pt:Ser/Plas:Qn


name: Deprecated Renal function panel & Glomerular filtration rate.predicted


name: Renal function panel & Glomerular filtration rate.predicted


name: 17-Ketosteroids^post high dose dexamethasone:MRat:24H:Urine:Qn


name: 17-Ketosteroids^2D post high dose dexamethasone:MRat:24H:Urine:Qn


name: 2-Dechloroethylifosfamide^1D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 2-Dechloroethylifosfamide^2D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 2-Dechloroethylifosfamide^3D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 2-Dechloroethylifosfamide^4D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 2-Dechloroethylifosfamide^5D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 2-Dechloroethylifosfamide^3H post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 2-Dechloroethylifosfamide^6H post dose ifosfamide:MCnc:Pt:Bld:Qn


name: Deprecated 3-Hydroxytetradecanoylcarnitine (C14-OH) [Molecules/volume] in Serum or Plasma


name: 3-Dechloroethylifosfamide^1D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 3-Dechloroethylifosfamide^2D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 3-Dechloroethylifosfamide^3D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 3-Dechloroethylifosfamide^4D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 3-Dechloroethylifosfamide^6D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 3-Dechloroethylifosfamide^3H post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 3-Dechloroethylifosfamide^6H post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^1D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^2D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^3D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^4D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^5D post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^3H post dose ifosfamide:MCnc:Pt:Bld:Qn


name: 4-Hydroxyifosfamide^6H post dose ifosfamide:MCnc:Pt:Bld:Qn


name: Respiratory syncytial virus Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: SLC6A4 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Alpha-beta crystallin Ag:PrThr:Pt:Tiss:Ord:Immune stain


name: carBAMazepine & metabolites panel:-:Pt:Ser/Plas:-


name: Deprecated Cholesterol [Mass/volume] in blood


name: Parvovirus B19 DNA:PrThr:Pt:Body fld:Ord:Probe.amp.tar


name: Parvovirus B19 DNA:PrThr:Pt:Bone mar:Ord:Probe.amp.tar


name: Parvovirus B19 DNA:PrThr:Pt:Amnio fld:Ord:Probe.amp.tar


name: Platelet glycoprotein IIb-IIIa Ab:PrThr:Pt:Ser:Ord


name: Eosinophils.band form/Cells:NFr:Pt:Bone mar:Qn:Manual count


name: Lupus anticoagulant neutralization.dilute phospholipid actual/Normal:RelTime:Pt:PPP:Qn:Coag


name: Lupus anticoagulant neutralization.dilute phospholipid actual/Normal


name: von Willebrand factor.collagen binding activity actual/Normal:RelRto:Pt:PPP:Qn:IA


name: von Willebrand factor.collagen binding activity actual/Normal


name: von Willebrand factor.collagen binding activity/von Willebrand factor Ag:Ratio:Pt:PPP:Qn:IA


name: von Willebrand factor.collagen binding activity/von Willebrand factor Ag


name: Creatinine dialysis fluid clearance/1.73 sq M:ArVRat:Pt:Dial fld+Ser/Plas:Qn


name: Creatinine renal clearance/1.73 sq M.predicted.female:ArVRat:Pt:Ser/Plas:Qn:Cockcroft-Gault formula, BSA formula


name: Creatinine renal clearance/1.73 sq M.predicted.female


name: Creatinine renal clearance/1.73 sq M.predicted.male:ArVRat:Pt:Ser/Plas:Qn:Cockcroft-Gault formula, BSA formula


name: Creatinine renal clearance/1.73 sq M.predicted.male


name: Glomerular filtration rate:ArVRat:Pt:Ser/Plas/Bld:Qn:Creatinine-based formula (Schwartz)/1.73 sq M


name: Observation:Prid:Pt:Bronchial brush:Nom:Cyto stain.thin prep


name: Coagulation factor II circulating inhibitor:PrThr:Pt:PPP:Ord


name: Coagulation factor II circulating inhibitor


name: Coagulation:PrThr:Pt:PPP:Ord:Coag.Surface induced circulating inhibitor


name: Molecular diagnostic major findings for display:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Molecular diagnostic major findings for display


name: Molecular diagnostic overall interpretation:PrThr:Pt:Bld/Tiss:Ord:Molgen


name: Molecular diagnostic overall interpretation


name: Body temperature^post transfusion reaction:Temp:Pt:^Patient:Qn


name: Blood group antibody titered:Prid:Pt:Ser/Plas:Nom


name: Blood pressure systolic & diastolic^post transfusion:Pres:Pt:Arterial system:Qn


name: Blood pressure systolic & diastolic^pre transfusion:Pres:Pt:Arterial system:Qn


name: Patient symptoms^post transfusion reaction:Imp:Pt:^Patient:Nar


name: Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid:Ratio:Pt:PPP:Qn:Coag


name: Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid


name: Corticotropin^pre 1 mg dexamethasone PO overnight:MCnc:Pt:Plas:Qn


name: Corticotropin^post 1 mg dexamethasone PO overnight:MCnc:Pt:Plas:Qn


name: Cortisol^pre 2 mg dexamethasone PO overnight:MCnc:Pt:Ser/Plas:Qn


name: Cortisol^post 2 mg dexamethasone PO overnight:MCnc:Pt:Ser/Plas:Qn


name: Corticotropin^pre 2 mg dexamethasone PO overnight:MCnc:Pt:Plas:Qn


name: Corticotropin^post 2 mg dexamethasone PO overnight:MCnc:Pt:Plas:Qn


name: Corticotropin^pre 500 ug dexamethasone PO 2.5 day low dose q6h:MCnc:Pt:Plas:Qn


name: Corticotropin^post 500 ug dexamethasone PO 2.5 day low dose q6h:MCnc:Pt:Plas:Qn


name: Cortisol^pre 100 ug CRH IV:MCnc:Pt:Ser/Plas:Qn


name: Cortisol^20M post 100 ug CRH IV:MCnc:Pt:Ser/Plas:Qn


name: Cortisol^40M post 100 ug CRH IV:MCnc:Pt:Ser/Plas:Qn


name: Cortisol^1H post 100 ug CRH IV:MCnc:Pt:Ser/Plas:Qn


name: Corticotropin^pre 100 ug CRH IV:MCnc:Pt:Plas:Qn


name: Corticotropin^20M post 100 ug CRH IV:MCnc:Pt:Plas:Qn


name: Corticotropin^40M post 100 ug CRH IV:MCnc:Pt:Plas:Qn


name: Corticotropin^1H post 100 ug CRH IV:MCnc:Pt:Plas:Qn


name: Cortisol^30M pre dose insulin IV:MCnc:Pt:Ser/Plas:Qn


name: Cortisol^20M post dose insulin IV:MCnc:Pt:Ser/Plas:Qn


name: Somatotropin^30M pre dose arginine:MCnc:Pt:Ser/Plas:Qn


name: Somatotropin^20M post dose arginine:MCnc:Pt:Ser/Plas:Qn


name: Plasma cells/Leukocytes:NFr:Pt:Body fld:Qn:Manual count


name: (Views) + (view AP^W standing):Find:Pt:Lower extremity.bilateral>Knee:Doc:XR


name: Guidance for transjugular placement of transjugular intrahepatic portosystemic shunt:Find:Pt:Abdomen>Portal vein+Hepatic vein:Doc:RF.angio


name: Guidance for transjugular placement of transjugular intrahepatic portosystemic shunt


name: Thyrotropin^20M post dose TRH:ACnc:Pt:Ser/Plas:Qn


name: Bacterial susceptibility panel:-:Pt:Isolate:OrdQn:Agar diffusion


name: Eastern equine encephalitis virus RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Urinalysis microscopic panel:NCnc:Pt:Urine:Qn:Automated count


name: Urinalysis dipstick panel:-:Pt:Urine:-:Test strip.automated


name: OTC - Keep out of reach of children section:-:-:^FDA product label:Nar


name: OTC - Keep out of reach of children section


name: OTC - Stop use section:-:-:^FDA product label:Nar


name: OTC - When using section:-:-:^FDA product label:Nar


name: OTC - Ask doctor or pharmacist section:-:-:^FDA product label:Nar


name: OTC - Ask doctor section:-:-:^FDA product label:Nar


name: OTC - Do not use section:-:-:^FDA product label:Nar


name: VFD Type C medicated feed animal drug label:-:-:^FDA product label:Nar


name: VFD Type C medicated feed animal drug label


name: VFD Type B medicated feed animal drug label:-:-:^FDA product label:Nar


name: VFD Type B medicated feed animal drug label


name: OTC Type C medicated feed animal drug label:-:-:^FDA product label:Nar


name: OTC Type C medicated feed animal drug label


name: OTC Type B medicated feed animal drug label:-:-:^FDA product label:Nar


name: OTC Type B medicated feed animal drug label


name: VFD Type A medicated article animal drug label:-:-:^FDA product label:Nar


name: VFD Type A medicated article animal drug label


name: OTC Type A medicated article animal drug label:-:-:^FDA product label:Nar


name: OTC Type A medicated article animal drug label


name: OTC animal drug label:-:-:^FDA product label:Nar


name: Prescription animal drug label:-:-:^FDA product label:Nar


name: Maternal screen for fetal abnormalities such as Open Neural Tube Defects, Trisomy 21 or Trisomy 18 panel:-:Pt:Ser/Plas:-


name: Maternal screen for fetal abnormalities such as Open Neural Tube Defects, Trisomy 21 or Trisomy 18 panel


name: Adenosine monophosphate.cyclic stimulation panel:-:Pt:Urine:Qn


name: Adenosine monophosphate.cyclic stimulation panel


name: Glucose tolerance gestational panel:-:Pt:Urine+Ser/Plas:-


name: Glucose screen gestational panel:-:Pt:Urine+Ser/Plas:-


name: Lactose challenge panel:-:Pt:Exhl gas:Qn


name: Triple bolus stimulation panel:-:Pt:Ser/Plas:Qn


name: Glucose tolerance 3H panel:-:-:Ser/Plas:Qn


name: Glucose tolerance 4H panel:-:-:Ser/Plas:Qn


name: Glucose tolerance 5H panel:-:-:Ser/Plas:Qn


name: Glucose tolerance 6H panel:-:-:Ser/Plas:Qn


name: Hydrogen/Expired gas^pre XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^4H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Neisseria meningitidis serogroups Ag panel:-:Pt:XXX:-:LA


name: Neisseria meningitidis serogroups Ag panel


name: Glucose tolerance 3H gestational panel:-:-:Ser/Plas:Qn


name: Alpha-1-Fetoprotein^^adjusted for multiple gestations:MoM:Pt:Ser/Plas:Qn


name: Chlamydophila pneumoniae Ab.IgA & IgG & IgM:Imp:Pt:Ser:Nom


name: Hydrogen/Expired gas^3.5H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^4.5H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^5H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^5.5H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: Hydrogen/Expired gas^6H post XXX challenge:VFr:Pt:Exhl gas:Qn


name: HTT gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: AS gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: HIV 1 RNA panel:-:Pt:CSF:Qn:Probe.amp.tar


name: Ova & parasites:Prid:Pt:Bld/Tiss:Nom:Wright stain


name: DMD gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Immunoglobulin heavy chain gene rearrangements:Find:Pt:Bld/Tiss:Nar:Molgen


name: Liver kidney microsomal Ab.IgG:Titr:Pt:Ser:SemiQn


name: Gentamicin:Susc:Pt:Isolate:OrdQn:Method for Slow-growing mycobacteria


name: Cefepime:Susc:Pt:Isolate:OrdQn:Method for Slow-growing mycobacteria


name: Cefotaxime:Susc:Pt:Isolate:OrdQn:Method for Slow-growing mycobacteria


name: Coagulation factor XIII inhibitor:PrThr:Pt:PPP:Ord:Chromo


name: Bixa orellana seed Ab.IgE:ACnc:Pt:Ser:Qn


name: Human papilloma virus 6+11+42+43+44 DNA:PrThr:Pt:Anal:Ord:Probe.amp.sig


name: Latex recombinant (rHev b) 1 Ab.IgE:ACnc:Pt:Ser:Qn


name: Latex recombinant (rHev b) 11 Ab.IgE:ACnc:Pt:Ser:Qn


name: Latex recombinant (rHev b) 6.01 Ab.IgE:ACnc:Pt:Ser:Qn


name: Latex recombinant (rHev b) 6.02 Ab.IgE:ACnc:Pt:Ser:Qn


name: Lupinus albus seed Ab.IgE:ACnc:Pt:Ser:Qn


name: (Arachis hypogaea+Cow milk+Egg white+Mustard) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: (Actinidia chinensis+Beef+Pandalus borealis+Sesamum indicum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: (Acer negundo+Betula verrucosa+Corylus avellana+Quercus alba+Platanus acerifolia) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: (Anthoxanthum odoratum+Lolium perenne+Phleum pratense+Secale cereale+Holcus lanatus) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: (Actinidia chinensis+Corylus avellana+Musa spp+Pandalus borealis) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: (Corylus avellana+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: (Allium cepa+Allium sativum+Sesamum indicum+Yeast) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk


name: Herpes simplex virus 1 DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Herpes simplex virus 1 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Herpes simplex virus 2 DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Herpes simplex virus 2 DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar


name: Nuclear matrix protein 22:PrThr:Pt:Urine:Ord


name: Semen analysis post vasectomy panel:-:Pt:Semen:-


name: First trimester maternal screen with nuchal translucency:Imp:Pt:^Patient:Nom


name: Thyroxine binding protein pattern:Imp:Pt:Ser/Plas:Nom:Electrophoresis


name: Staphylococcus aureus toxic shock syndrome toxin 1+Staphylococcus aureus enterotoxin B Ab:PrThr:Pt:Ser:Ord


name: Deprecated 11-Dehydro thromboxane beta 2/Creatinine [Mass Ratio] in Urine


name: 11-Dehydro thromboxane beta 2/Creatinine


name: Plasmodium sp lactate dehydrogenase:Prid:Pt:Bld:Nom


name: Coxsackievirus A9+B1+B2+B3+B4+B5+B6 Ab:Titr:Pt:Ser:SemiQn:Comp fix


name: Parainfluenza virus 1+2+3 Ab:Titr:Pt:Ser:SemiQn:Comp fix


name: Influenza virus A+B Ab:Titr:Pt:Ser:SemiQn:Comp fix


name: Influenza virus A.neuraminidase inhibitor resistance:Susc:Pt:Isolate:Ord:Phenotyping


name: Influenza virus A.neuraminidase inhibitor resistance


name: Influenza virus A nucleoprotein RNA:PrThr:Pt:Isolate:Ord:Sequencing


name: Influenza virus A non-structural protein RNA:PrThr:Pt:Isolate:Ord:Sequencing


name: Influenza virus A polymerase A RNA:PrThr:Pt:Isolate:Ord:Sequencing


name: Influenza virus A polymerase B1 cDNA:PrThr:Pt:Isolate:Ord:Sequencing


name: Influenza virus A polymerase B2 RNA:PrThr:Pt:Isolate:Ord:Sequencing


name: Influenza virus B Ab:Titr:Pt:Ser:SemiQn:HAI


name: Influenza virus susceptibility panel:-:Pt:Isolate:-


name: Influenza virus A polymerase RNA:Prid:Pt:Isolate:Nom:Sequencing


name: Influenza virus.neuraminidase inhibitor resistance:Susc:Pt:Isolate:Ord


name: Influenza virus.neuraminidase inhibitor resistance:Susc:Pt:Isolate:Ord:Genotyping


name: 11-Deoxycortisol^7th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^6th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^5th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^4th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^3rd specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: 11-Deoxycortisol^1st specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: VKORC1 gene targeted mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen


name: Reticulum cell/Cells:NFr:Pt:Bone mar:Qn:Gomori stain


name: Serotonin release 100 IU/mL heparin.unfractionated:ACnc:Pt:Ser:Qn


name: Serotonin release 0.1 IU/mL heparin.unfractionated:ACnc:Pt:Ser:Qn


name: Serotonin release 100 IU/mL heparin.low molecular weight:ACnc:Pt:Ser:Qn


name: Serotonin release 0.1 IU/mL heparin.low molecular weight:ACnc:Pt:Ser:Qn


name: Safe handling warning section:-:-:^FDA product label:Nar


name: Environmental warning section:-:-:^FDA product label:Nar


name: Food safety warning section:-:-:^FDA product label:Nar


name: Information for owners or caregivers section:-:-:^FDA product label:Nar


name: Information for owners or caregivers section


name: Veterinary indications section:-:-:^FDA product label:Nar


name: Platelet factor 4 Ag:PrThr:Pt:PPP:Ord:IA


name: Glucose^15M post 0.1 U/kg insulin:MCnc:Pt:Ser/Plas:Qn


name: Cortisol^15M post dose insulin IV:MCnc:Pt:Ser/Plas:Qn


name: Somatotropin^15M post dose insulin IV:MCnc:Pt:Ser/Plas:Qn


name: Multisection^W contrast IV:Find:Pt:Lower extremity.bilateral:Doc:CT


name: Herpes simplex virus 1 Ab.IgM:Titr:Pt:Ser:SemiQn:IF


name: Coagulation:Time:Pt:PPP:Qn:Coag.surface induced.lupus sensitive.factor substitution.1H post incubation after addition of normal plasma


name: Ganglioside GD1a Ab.IgG/Ganglioside GD1a Ab.IgM:Ratio:Pt:Ser:Qn:IA


name: Ganglioside GD1a Ab.IgG/Ganglioside GD1a Ab.IgM


name: Ganglioside GD1b Ab.IgG/Ganglioside GD1b Ab.IgM:Ratio:Pt:Ser:Qn:IA


name: Ganglioside GD1b Ab.IgG/Ganglioside GD1b Ab.IgM


name: Asialoganglioside GM1 Ab.IgG/Asialoganglioside GM1 Ab.IgM:Ratio:Pt:Ser:Qn:IA


name: Asialoganglioside GM1 Ab.IgG/Asialoganglioside GM1 Ab.IgM


name: Ganglioside GM1 Ab.IgG/Ganglioside GM1 Ab.IgM:Ratio:Pt:Ser:Qn:IA


name: Ganglioside GM1 Ab.IgG/Ganglioside GM1 Ab.IgM


name: Ganglioside GM2 Ab.IgG/Ganglioside GM2 Ab.IgM:Ratio:Pt:Ser:Qn:IA


name: Ganglioside GM2 Ab.IgG/Ganglioside GM2 Ab.IgM


name: Ganglioside GQ1b Ab.IgG/Ganglioside GQ1b Ab.IgM:Ratio:Pt:Ser:Qn:IA


name: Ganglioside GQ1b Ab.IgG/Ganglioside GQ1b Ab.IgM


name: ABO & Rh group^post transfusion reaction:Type:Pt:Bld^Newborn:Nom


name: Primary reason for assessment:Type:Pt:^Patient:Nom:MDS.full


name: Hemoglobin pattern:Imp:Pt:Bld:Nom:Electrophoresis pH 6.0


name: XXX blood group Ab.IgM:Titr:Pt:Ser/Plas:SemiQn


name: Hepatitis B virus surface Ag:PrThr:Pt:Bld^Donor:Ord:Neut


name: Epstein Barr virus early diffuse Ab.IgG:ACnc:Pt:Ser:Qn


name: XXX blood group Ab:Titr:Pt:Ser/Plas:SemiQn:Antihuman globulin


name: Paragonimus sp Ab:Titr:Pt:Plr fld:SemiQn


name: Parainfluenza virus 1+2+3 Ab:Titr:Pt:Ser:SemiQn


name: Calcium.ionized^^adjusted to pH 7.4:SCnc:Pt:Body fld:Qn


name: Mycobacterium sp:PrThr:Pt:XXX:Ord:Organism specific culture


name: Reasons for assessment (full):-:Pt:^Patient:Set


name: Platelet aggregation interpretation:Imp:Pt:PRP:Ord:Adenosine diphosphate induced.20 umol/L


name: Platelet aggregation interpretation:Imp:Pt:PRP:Ord:Adenosine diphosphate induced.2 umol/L


name: Platelet aggregation interpretation:Imp:Pt:PRP:Ord:Adenosine diphosphate induced.4 umol/L


name: Platelet aggregation interpretation:Imp:Pt:PRP:Ord:Collagen induced.190 ug/mL


name: Indirect antiglobulin test.XXX reagent^post transfusion:PrThr:Pt:Ser/Plas:Ord


name: Indirect antiglobulin test.XXX reagent:PrThr:Pt:Ser/Plas:Ord


name: XXX blood group Ab.IgG:Titr:Pt:Ser/Plas:SemiQn


name: Cytology report:Find:Pt:Bronchial brush:Doc:Cyto stain


name: pH^^adjusted to patient's actual temperature:LsCnc:Pt:BldMV:SemiQn


name: Carbon dioxide^^adjusted to patient's actual temperature:PPres:Pt:BldMV:Qn


name: Horowitz index^^adjusted to patient's actual temperature:Ratio:Pt:Bld+Inhl gas:Qn


name: BRCA1+BRCA2 gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: HBB gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: CFTR gene mutations tested for:Num:Pt:Bld/Tiss:Qn:Molgen


name: Leishmania donovani Ab.IgG & IgM:Imp:Pt:Ser:Nom


name: Leishmania tropica Ab.IgG & IgM:Imp:Pt:Ser:Nar


name: Direct antiglobulin test.XXX reagent:PrThr:Pt:RBC:Ord


name: Direct antiglobulin test.XXX reagent^post transfusion:PrThr:Pt:RBC:Ord


name: Triticum aestivum native (nTri a) 19 Ab.IgE:ACnc:Pt:Ser:Qn


name: CD117 Ag:PrThr:Pt:Bone mar:Ord:Immune stain


name: CD15 Ag:PrThr:Pt:Bone mar:Ord:Immune stain


name: Streptococcus pneumoniae capsular polysaccharide Ab.IgG:MCnc:Pt:Ser:Qn:IA


name: Streptococcus pneumoniae capsular polysaccharide Ab.IgG2:MCnc:Pt:Ser:Qn:IA


name: 17-Hydroxyprogesterone^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Testosterone^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Aldosterone^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Corticotropin^pre or post XXX challenge:SCnc:Pt:Plas:Qn


name: Cortisol^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: EPINEPHrine^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Glucose^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Insulin^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Lactate^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Norepinephrine^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn


name: Calcitonin^pre or post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Gastrin^pre or post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Prolactin^pre or post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Renin^pre or post XXX challenge:MCnc:Pt:Plas:Qn


name: Somatotropin^pre or post XXX challenge:MCnc:Pt:Ser/Plas:Qn


name: Paragonimus sp Ab:Titr:Pt:Plr fld:SemiQn:IA


name: Coccidioides immitis Ab:Titr:Pt:Body fld:SemiQn